tiprankstipranks
Trending News
More News >

Acura Pharmaceuticals Faces Financial Challenges Amid New Loans

Story Highlights
Acura Pharmaceuticals Faces Financial Challenges Amid New Loans

Don’t Miss TipRanks’ Half-Year Sale

Acura Pharmaceuticals ( (ACUR) ) has shared an update.

On June 3 and June 20, 2025, Acura Pharmaceuticals received loans totaling $200,000 from Abuse Deterrent Pharma, LLC, contributing to a principal balance of $8,194,279 with accrued interest of approximately $721,000. The loans are crucial for maintaining daily operations, but without additional financing by mid-July 2025, Acura may need to scale back operations or consider bankruptcy, potentially resulting in a complete loss of shareholder value.

More about Acura Pharmaceuticals

Acura Pharmaceuticals operates in the pharmaceutical industry, focusing on the development of products utilizing its proprietary LIMITx and Impede technologies. The company is involved in creating abuse-deterrent formulations and has a market focus on addressing opioid abuse.

Average Trading Volume: 6,850

Technical Sentiment Signal: Sell

Current Market Cap: $165K

For detailed information about ACUR stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1